MycoFlora

The Basics

This dairy and lactose-free probiotic strengthens the gastrointestinal environment, combats the growth of bad bacteria and creates a healthier balance of beneficial microflora.

Delivering the key gut organism, Saccaromyces boulardii, derived from non-GMO Lytchi fruits, MycoFlora is often used to address imbalances associated with

• Lyme disease
• Inflammatory bowel syndrome
• Irritable bowel syndromes, such as those caused by Crohn’s disease and ulcerative colitis
• Bacterial complications of short bowel syndrome
• Relapsing Clostridium difficile
• Diarrhea, traveler’s diarrhea and diarrhea associated with antibiotic use

How to take it

Take 2 capsules a day at any time or as directed by your health care practitioner.

Contents

60 Vegetarian Capsules

Back to top

Product Ingredients

MYCOFLORA

Directions

As a dietary supplement, take 2 capsules a day at any time or as directed by your health care practitioner.

Formulated to exclude wheat, soy, gluten, eggs dairy, corn artificial colors, flavors, sugars or preservatives.

Store tightly closed in a cool, dry, dark place. Natural color, size and shape may vary between lots. Keep out of the reach of children

Manufactured in an NSF certified GMP registered facility.

Research

MYCOFLORA

Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells.
Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P.
Infect Immun. 2000 Oct;68(10):5998-6004.
PMID:10992512[PubMed - indexed for MEDLINE]
Free PMC Article
Related citations

Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections.
Elmer GW, Surawicz CM, McFarland LV.
JAMA. 1996 Mar 20;275(11):870-6. Review.
PMID:8596226[PubMed - indexed for MEDLINE]
Related citations

Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers.
Jahn HU, Ullrich R, Schneider T, Liehr RM, Schieferdecker HL, Holst H, Zeitz M.
Digestion. 1996;57(2):95-104.
PMID:8786007[PubMed - indexed for MEDLINE]
Related citations

Protective effect of Saccharomyces boulardii against the cholera toxin in rats.
Dias RS, Bambirra EA, Silva ME, Nicoli JR.
Braz J Med Biol Res. 1995 Mar;28(3):323-5.
PMID:8520525[PubMed - indexed for MEDLINE]
Related citations

Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.
Buts JP, Corthier G, Delmee M.
J Pediatr Gastroenterol Nutr. 1993 May;16(4):419-25.
PMID:8315551[PubMed - indexed for MEDLINE]
Related citations

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum.
Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I, Lamont JT.
Gastroenterology. 1993 Apr;104(4):1108-15.
PMID:8462799[PubMed - indexed for MEDLINE]
Related citations

Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract.
Corthier G, Lucas F, Jouvert S, Castex F.
Toxicon. 1992 Dec;30(12):1583-9.
PMID:1488767[PubMed - indexed for MEDLINE]
Related citations

Antibiotic-associated diarrhea.
Bartlett JG.
Clin Infect Dis. 1992 Oct;15(4):573-81. Review.
PMID:1420669[PubMed - indexed for MEDLINE]
Related citations

Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice.
Elmer GW, Corthier G.
Can J Microbiol. 1991 Apr;37(4):315-7.
PMID:1913342[PubMed - indexed for MEDLINE]
Related citations

Probiotics in human medicine.
Fuller R.
Gut. 1991 Apr;32(4):439-42. Review. No abstract available.
PMID:1902810[PubMed - indexed for MEDLINE]
Free PMC Article
Related citations

Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii.
Buts JP, Bernasconi P, Vaerman JP, Dive C.
Dig Dis Sci. 1990 Feb;35(2):251-6.
PMID:2302983[PubMed - indexed for MEDLINE]
Related citations

Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.
Elmer GW, McFarland LV.
Antimicrob Agents Chemother. 1987 Jan;31(1):129-31.
PMID:3566236[PubMed - indexed for MEDLINE]
Free PMC Article
Related citations

Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii.
Toothaker RD, Elmer GW.
Antimicrob Agents Chemother. 1984 Oct;26(4):552-6.
PMID:6517545[PubMed - indexed for MEDLINE]
Free PMC Article
Related citations

Reviews

Write a review: